<DOC>
	<DOCNO>NCT00113802</DOCNO>
	<brief_summary>The purpose study determine whether epratuzumab provide effective therapy Waldenström 's Macroglobulinemia ( WM ) .</brief_summary>
	<brief_title>Study Epratuzumab ( hLL2 ) Patients With Waldenstrom 's Macroglobulinemia</brief_title>
	<detailed_description>This multi-center , single-arm study epratuzumab patient Waldenström 's Macroglobulinemia ( WM ) fail chemotherapy . After baseline evaluation , patient receive epratuzumab infuse approximately 30-60 minute 360 mg/m2 , administer weekly 4 consecutive week ( day 1 , 8 , 15 , 22 ) . Post-treatment evaluation occur day last infusion , 6 12 week . Patients without progression disease continue long-term follow disease progression least 5 year , evaluation every 3 month 2 year , semi-annually . Otherwise , follow-up required resolution treatment related abnormality .</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Documented diagnosis Waldenström 's Macroglobulinemia use criterion propose 2nd International Workshop WM , Athens , Greece , 2002 . Measurable disease , define serum monoclonal IgM protein ≥1000 mg/dL electrophoresis . Lymphoplasmacytic infiltration bone marrow &gt; 10 % involvement . Failed least one , 3 , regimen ( ) prior therapy . ( Please consult study site full eligibility criterion )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Epratuzumab ( hLL2- anti-CD22 humanize antibody )</keyword>
	<keyword>Waldenstrom 's Macroglobulinemia</keyword>
	<keyword>Waldenstrom Macroglobulinemia</keyword>
	<keyword>Hematologic Disease</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Paraproteinemias</keyword>
	<keyword>Vascular Hemostatic Disorders</keyword>
	<keyword>Lymphoproliferative Disorders</keyword>
</DOC>